Introduction. Homocysteine is an amino acid that is formed in the metabolism of methionine as the quantitatively most important metabolite. Its chemical structure has been known for 90 years and its biological roles are still being investigated. Under normal conditions, homocysteine is present in plasma at the concentration of 5 - 9 mmol/l. When the cell capacity for homocysteine is reached, it is transported to the extracellular space, until the intracellular level is normalized. If the cell is unable to reach the required levels of homocysteine, it accumulates in the blood and hyperhomocysteinemia occurs. Discussion. It has been determined that many factors, such as congenital enzyme deficiency, age, sex, inadequate diet (vitamin B complex deficiency) increase the level of homocysteine in the blood. Impaired kidney function, diabetes, hyperthyroidism, as well as many medications, can have an effect on homecysteinemia. Increased concentration of homocysteine in the blood accelerates the process of atherosclerosis by several different mechanisms and represents an independent risk factor for the occurrence of cardiovascular diseases and adverse cerebral events. The prevalence of hyperhomocysteinemia is estimated at 5% in the general population and 13 - 47% among patients with symptomatic atherosclerotic vascular disease. Conclusion. For these reasons, the level of homocysteine in the blood should be monitored and corrective measures should be implemented, which include sufficient intake of folic acid, vitamins B12 and B6, in doses that depend on fasting homocysteine levels and after the methionine load test.
References
1.
Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews. 2021(9).
2.
Cohen E, Margalit I, Shochat T, Goldberg E, Krause I. Gender differences in homocysteine concentrations, a population-based cross-sectional study. Nutrition, Metabolism and Cardiovascular Diseases. 2019;29(1):9–14.
3.
Osadnik T, Pawlas N, Lejawa M, Lisik M, Osadnik K, Fronczek M, et al. Genetic and environmental factors associated with homocysteine concentrations in a population of healthy young adults. Analysis of the MAGNETIC study. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(6):939–47.
4.
Duthie SJ, Duthie GG, Russell WR, Kyle JAM, Macdiarmid JI, Rungapamestry V, et al. Effect of increasing fruit and vegetable intake by dietary intervention on nutritional biomarkers and attitudes to dietary change: a randomised trial. European Journal of Nutrition. 2018;57(5):1855–72.
5.
de Oliveira JJ, e Silva A de S, Ribeiro AGSV, Barbosa CGR, de Oliveira Silva JA, Pontes AG, et al. The effect of physical activity on total homocysteine concentrations and cardiovascular risk in older Brazilian adults with type 2 diabetes. Journal of Diabetes & Metabolic Disorders. 2021;20(1):407–16.
6.
Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle—biochemistry, pathways, and regulation. Journal of Inherited Metabolic Disease. 2019;42(4):673–85.
7.
Kaye AD, Jeha GM, Pham AD, Fuller MC, Lerner ZI, Sibley GT, et al. Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. Advances in Therapy. 2020;37(10):4149–64.
8.
Katsiki N, Perez-Martinez P, Mikhailidis DP. Homocysteine and Non-Cardiac Vascular Disease. Current Pharmaceutical Design. 2017;23(22).
9.
Vezzoli A, Dellanoce C, Maria Caimi T, Vietti D, Montorsi M, Mrakic-Sposta S, et al. Influence of Dietary Supplementation for Hyperhomocysteinemia Treatments. Nutrients. 12(7):1957.
10.
Nikolić M, Jović S. Ishrana i zdravlje. In: Dijetetika, Niš: Medicinski fakultet, WUS 2007. p. 11–40.
11.
Tian T, Yang KQ, Cui JG, Zhou LL, Zhou XL. Folic Acid Supplementation for Stroke Prevention in Patients With Cardiovascular Disease. The American Journal of the Medical Sciences. 2017;354(4):379–87.
12.
Brown MJ, Ameer MA, Beier K. Vitamin B6 Deficiency. In: StatPearls [Internet] Treasure Island. 2021.
13.
Xu R, Huang F, Wang Y, Liu Q, Lv Y, Zhang Q. Gender- and age-related differences in homocysteine concentration: a cross-sectional study of the general population of China. Scientific Reports. 10(1).
14.
Živković V. Uloga homocisteina u nastanku kardiovaskularnih bolesti. Diplomski rad, Medicinski fakultet Univerziteta u Nišu. 2021;
15.
Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician. 2017;96(6):384–9.
16.
Nikolić M, Miladinović B, Perović M. Fruit and vegetables as functional food in primary prevention of cardiovascular disease. Zdravstvena zastita. 2017;46(4):47–53.
17.
Esse R, Barroso M, Tavares de Almeida I, Castro R. The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art. International Journal of Molecular Sciences. 20(4):867.
18.
Niu X, Chen J, Wang J, Li J, Zeng D, Wang S, et al. A Cross‐sectional Study on the Relationship Between Homocysteine and Lipid Profiles Among Chinese Population from Hunan. Lipids. 2021;56(1):93–100.
19.
Miñana G, Gil-Cayuela C, Fácila L, Bodi V, Valero E, Mollar A, et al. Homocysteine and long-term recurrent infarction following an acute coronary syndrome. Cardiology Journal. 28(4):598–606.
20.
Zhu M, Mao M, Lou X. Elevated homocysteine level and prognosis in patients with acute coronary syndrome: a meta-analysis. Biomarkers. 2019;24(4):309–16.
21.
Li N, Tian L, Ren J, Li Y, Liu Y. Evaluation of Homocysteine in the Diagnosis and Prognosis of Coronary Slow Flow Syndrome. Biomarkers in Medicine. 2019;13(17):1439–46.
22.
Vasan RS, Beiser A, D’Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma Homocysteine and Risk for Congestive Heart Failure in Adults Without Prior Myocardial Infarction. JAMA. 2003;289(10):1251.
23.
Kang SS, Rosenson RS. Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease. Cardiovascular Drugs and Therapy. 2018;32(2):233–40.
24.
Al Mutairi F. Hyperhomocysteinemia: Clinical Insights. Journal of Central Nervous System Disease. 2020;12:117957352096223.
25.
Dunn J, Title LM, Bata I, Johnstone DE, Kirkland SA, O’Neill BJ, et al. Relation of a Common Mutation in Methylenetetrahydrofolate Reductase to Plasma Homocysteine and Early Onset Coronary Artery Disease. Clinical Biochemistry. 1998;31(2):95–100.
26.
Bai MF, Wang X. Risk factors associated with coronary heart disease in women: a systematic review. Herz. 2020;45(S1):52–7.
27.
Nikolić M. The importance of nutrition in secondary prevention and rehabilitation of coronary artery disease. Srce i krvni sudovi. 2011;30(4):206–9.
28.
Branković S, Miladinović B, Radenković M, Gočmanac Ignjatović M, Kostić M, Šavikin K, et al. Hypotensive, cardiodepressant, and vasorelaxant activities of black currant (Ribes nigrum ‘Ben Sarek’) juice. Canadian Journal of Physiology and Pharmacology. 2016;94(10):1102–5.
29.
Houston M. The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease. Therapeutic Advances in Cardiovascular Disease. 2018;12(3):85–108.
30.
Nikolić M. Glikemijski indeks namirnica i glikemijsko opterećenje kao faktori rizika za ishemijsku bolest srca (doktorska disertacija. Niš: Medicinski fakultet. 2004;
31.
Halasz G, Piepoli MF. Focus on atherosclerosis and lipids. European Journal of Preventive Cardiology. 2020;27(15):1571–4.
32.
Ruiz-León AM, Lapuente M, Estruch R, Casas R. Clinical Advances in Immunonutrition and Atherosclerosis: A Review. Frontiers in Immunology. 10.
33.
Kopin L, Lowenstein CJ. Dyslipidemia. Annals of Internal Medicine. 2017;167(11):ITC81–96.
34.
Carson NAJ, Cusworth DC, Dent CE, Field CMB, Neill DW, Westall RG. Homocystinuria: A new inborn error of Metabolism associated with Mental Deficiency. Archives of Disease in Childhood. 1963;38(201):425–36.
35.
McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111–28.
36.
McCully KS. Homocysteine theory of arteriosclerosis: Development and current status. Athreroscl rev. 1983;11:157–246.
37.
Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, et al. Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation. 2019;139(13):1603–11.
38.
Ducker GS, Rabinowitz JD. One-Carbon Metabolism in Health and Disease. Cell Metabolism. 2017;25(1):27–42.
39.
Mirković D, Majkić N, Ignjatović S. Homocistein: Hemija, metabolizam i uloga u patofiziološkim procesima. Jugoslov Med Biohem. 2003;22:127–40.
40.
Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Archives of Pharmacal Research. 2018;41(4):372–83.
41.
Zaric BL, Obradovic M, Bajic V, Haidara MA, Jovanovic M, Isenovic ER. Homocysteine and Hyperhomocysteinaemia. Current Medicinal Chemistry. 2019;26(16):2948–61.
42.
Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Review of Cardiovascular Therapy. 2018;16(8):559–65.
43.
Morris AAM, Kožich V, Santra S, Andria G, Ben‐Omran TIM, Chakrapani AB, et al. Guidelines for the diagnosis and management of cystathionine beta‐synthase deficiency. Journal of Inherited Metabolic Disease. 2017;40(1):49–74.
44.
Bublil EM, Majtan T. Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020;173:48–56.
45.
Srećković M. Ispitivanje homocisteina kao markera ateroskleroze kod pacijenata sa metaboličkim sindromom, Doktorska disertacija. 2018;
46.
Guo W, Zhang H, Yang A, Ma P, Sun L, Deng M, et al. Homocysteine accelerates atherosclerosis by inhibiting scavenger receptor class B member1 via DNMT3b/SP1 pathway. Journal of Molecular and Cellular Cardiology. 2020;138:34–48.
47.
Zhao J, Chen H, Liu N, Chen J, Gu Y, Chen J, et al. Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis. Journal of Stroke and Cerebrovascular Diseases. 2017;26(12):2695–9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
